A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Phase 3 – large-scale trial before approval
Conditions:
Atrial Fibrillation
Sponsor: Janssen Research & Development, LLC
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Who can participate
Inclusion Criteria:
* Minimum age of 18 years
* Medically stable and appropriate for chronic antithrombotic treatment
* Atrial fibrillation eligible to receive anticoagulation
* Participant must satisfy one or both of the following categories of risk factors (a or b): a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of any type of stroke including symptomatic stroke of any kind. b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria:
* Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
* Any condition other than AF that requires chronic anticoagulation
Locations
37
Argentina (1)
Instituto de Investigaciones Clinicas Bahia Blanca
Bahía Blanca
Australia (1)
Flinders Medical Centre
Adelaide
Belgium (1)
Algemeen Stedelijk Ziekenhuis
Aalst
Brazil (1)
Hospital Felício Rocho
Belo Horizonte
Bulgaria (1)
MHAT Puls
Blagoevgrad
Canada (1)
The Governers of the University of Calgary
Calgery , Alberta
Chile (1)
Quantum Research
Puerto Varas
China (1)
Beijing Anzhen Hospital, Capital Medical University
БГ